(Q53248364)

English

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice.

scientific article published on 13 May 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8⁺ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

1 reference

based on heuristic

inferred from title

author name string

Y Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

Y Xie

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

T Chan

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

A Sami

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

S Ahmed

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

Q Liu

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

J Xiang

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

publication date

13 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

18

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

7

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

489-499

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

The neu oncogene encodes an epidermal growth factor receptor-related protein

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Herceptin: mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

T cell responses to Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Memory CD8 T-cell differentiation during viral infection

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Quantitative studies of CD8+ T-cell responses during microbial infection

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Recombinant viruses as a tool for therapeutic vaccination against human cancers

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Recombinant viral vectors: cancer vaccines

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

A high-efficiency Cre/loxP-based system for construction of adenoviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Effects of a SARS-associated coronavirus vaccine in monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Detailed analysis of the CD8+ T-cell response following adenovirus vaccination

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Elevated Frequencies of Self-reactive CD8+ T Cells following Immunization with a Xenoantigen Are Due to the Presence of a Heteroclitic CD4+ T-Cell Helper Epitope

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Current developments of immunotherapy in the clinic

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Future options with trastuzumab for primary systemic and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Anti-HER2 vaccines: new prospects for breast cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Multiplexed, real-time PCR for quantitative detection of human adenovirus

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Combinatorial synergy induced by adenoviral-mediated mda-7 and Herceptin in Her-2+ breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.18

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER-2-targeted therapy: lessons learned and future directions.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-producing NK Cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress on new vaccine strategies for the immunotherapy and prevention of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector

2 references

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

https://api.crossref.org/works/10.1038%2FCGT.2011.18

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estimation of liver tumor volume using different formulas - an experimental study in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

https://pubmed.ncbi.nlm.nih.gov/21566669

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/CGT.2011.18

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/21566669

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53248364&oldid=2212045866"